You are here: Industry Insights > Asthma

News List

Decreased Air Pollutants Linked to Less Childhood Asthma drugs
May 29, 2019
Decreased Air Pollutants Linked to Less Childhood Asthma.
For Many With Mild Asthma, Popular Rx May Not Work: Study drugs
May 22, 2019
A widely used type of asthma medication may not work in more than half of patients who are prescribed it, new research shows.
Cleaner Air Linked to Lower Asthma Rates in Kids drugs
May 22, 2019
Air pollution levels have been declining for years, and researchers can now show that cleaner air is linked to fewer kids developing asthma.
Mometasone, Tiotropium Do Not Top Placebo in Mild Asthma drugs
May 21, 2019
Mometasone, Tiotropium Do Not Top Placebo in Mild Asthma.
Sanofi gets EC approval for Dupixent to treat severe asthma pharmaceutical-technology
May 10, 2019
Sanofi’s Dupixent has been approved by the European Commission (EC) as an add-on maintenance treatment for severe asthma in adults and adolescents.
Summer Is Tough for Asthma Sufferers drugs
May 10, 2019
Summertime can bring asthma sufferers a lot of misery, but lung experts say watching for warning signs of breathing trouble can guard against serious complications.
Dupixent's on a roll in eczema and asthma, but COPD's a ‘much tougher’ malady fiercepharma
May 09, 2019
Armed with new nods in asthma and adolescent eczema, Regeneron’s Dupixent keeps reeling in new biologics patients.
Dupixent® Approved for Severe Asthma by European Commission americanpharmaceuticalreview
May 08, 2019
Regeneron Pharmaceuticals and Sanofi announced that the European Commission (EC) approved a new indication for Dupixent® (dupilumab) in asthma.
World Asthma Day: can fevipiprant revolutionise asthma treatment? pharmaceutical-technology
May 07, 2019
World Asthma Day aims to raise awareness of the burden of asthma. Increasingly, the standard of care for asthma, reliever and preventer inhalers, are being discovered to be insufficient in a number of ways.
GSK chases Trelegy asthma nod with mixed phase 3 results fiercepharma
May 06, 2019
With generics attacking Advair, GlaxoSmithKline has talked up prospects for 3-in-1 respiratory med Trelegy. Now, the company has data in hand that could help it move into the asthma arena—though it's not all positive.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page